Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. more
Time Frame | UTHR | Sector | S&P500 |
---|---|---|---|
1-Week Return | 9.71% | 0.67% | 0.78% |
1-Month Return | 14.84% | 0.42% | 2.95% |
3-Month Return | 33.39% | 0.84% | 4.47% |
6-Month Return | 44.79% | 9.71% | 16.17% |
1-Year Return | 41.68% | 13.01% | 27.26% |
3-Year Return | 75.38% | 22.89% | 35.66% |
5-Year Return | 307.74% | 70.09% | 101.24% |
10-Year Return | 260.28% | 184.41% | 234.88% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.45B | 1.48B | 1.69B | 1.94B | 2.33B | [{"date":"2019-12-31","value":62.25,"profit":true},{"date":"2020-12-31","value":63.73,"profit":true},{"date":"2021-12-31","value":72.42,"profit":true},{"date":"2022-12-31","value":83.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 117.60M | 108.10M | 122.50M | 146.70M | 257.50M | [{"date":"2019-12-31","value":45.67,"profit":true},{"date":"2020-12-31","value":41.98,"profit":true},{"date":"2021-12-31","value":47.57,"profit":true},{"date":"2022-12-31","value":56.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 1.33B | 1.38B | 1.56B | 1.79B | 2.07B | [{"date":"2019-12-31","value":64.31,"profit":true},{"date":"2020-12-31","value":66.43,"profit":true},{"date":"2021-12-31","value":75.51,"profit":true},{"date":"2022-12-31","value":86.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 91.88% | 92.71% | 92.73% | 92.42% | 88.94% | [{"date":"2019-12-31","value":99.08,"profit":true},{"date":"2020-12-31","value":99.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.67,"profit":true},{"date":"2023-12-31","value":95.91,"profit":true}] |
Operating Expenses | 1.52B | 781.60M | 1.01B | 809.90M | 885.10M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":51.46,"profit":true},{"date":"2021-12-31","value":66.31,"profit":true},{"date":"2022-12-31","value":53.32,"profit":true},{"date":"2023-12-31","value":58.28,"profit":true}] |
Operating Income | (187.60M) | 593.60M | 555.90M | 979.70M | 1.18B | [{"date":"2019-12-31","value":-15.83,"profit":false},{"date":"2020-12-31","value":50.1,"profit":true},{"date":"2021-12-31","value":46.92,"profit":true},{"date":"2022-12-31","value":82.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 24.90M | 50.40M | 36.10M | (16.30M) | 89.40M | [{"date":"2019-12-31","value":27.85,"profit":true},{"date":"2020-12-31","value":56.38,"profit":true},{"date":"2021-12-31","value":40.38,"profit":true},{"date":"2022-12-31","value":-18.23,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (165.00M) | 638.90M | 593.90M | 950.60M | 1.27B | [{"date":"2019-12-31","value":-12.95,"profit":false},{"date":"2020-12-31","value":50.14,"profit":true},{"date":"2021-12-31","value":46.61,"profit":true},{"date":"2022-12-31","value":74.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (60.50M) | 124.10M | 118.10M | 223.30M | 289.50M | [{"date":"2019-12-31","value":-20.9,"profit":false},{"date":"2020-12-31","value":42.87,"profit":true},{"date":"2021-12-31","value":40.79,"profit":true},{"date":"2022-12-31","value":77.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (104.50M) | 514.80M | 475.80M | 727.30M | 984.80M | [{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (104.50M) | 514.80M | 475.80M | 727.30M | 984.80M | [{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (104.50M) | 514.80M | 475.80M | 727.30M | 984.80M | [{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 11.28 | 11.58 | 10.03 | 15.02 | 19.84 | [{"date":"2019-12-31","value":56.85,"profit":true},{"date":"2020-12-31","value":58.37,"profit":true},{"date":"2021-12-31","value":50.55,"profit":true},{"date":"2022-12-31","value":75.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
UTHR | |
---|---|
Cash Ratio | 3.15 |
Current Ratio | 3.77 |
Quick Ratio | 3.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
UTHR | |
---|---|
ROA (LTM) | 12.25% |
ROE (LTM) | 20.08% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
UTHR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.22 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
UTHR | |
---|---|
Trailing PE | 14.62 |
Forward PE | 10.17 |
P/S (TTM) | 4.70 |
P/B | 1.83 |
Price/FCF | 41 |
EV/R | 3.72 |
EV/Ebitda | 6.24 |
PEG | 0.31 |
Medical devices are spearheading the digitalization of healthcare, reports analytics and software development company Luxoft . Specifically, medical devices are “providing accurate diagnoses, effective treatments and personalized care through advanced algorithms and patient data analysis.” Moreover, artificial intelligence (AI) is altering and improving the means by which many medical devices are created and work. Indeed, by quickly creating many prototypes based on design parameters and patient data, AI is allowing devices to be launched significantly faster and making them more effective. The latter development is likely lowering companies’ costs, while the former quality will probably enable them to charge more for their devices, raising revenue. AI can also allow each device to be tailored to individual patients’ needs. It is another development that will probably allow medical device makers to charge more for their offerings. For investors wanting to exploit these trends, here are the three best medical device stocks to buy.
Insider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR)
When it comes to seeking discounts, investors may do well with undervalued healthcare stocks . Primarily, that’s because with this sector, you’re dealing with a permanently relevant narrative. To be clear, that’s not to say that all healthcare enterprises are guaranteed to rise higher. However, this ecosystem directly addresses the human condition. By forwarding advanced solutions, society benefits over the long run as does the economy. Essentially, a healthier community is able to be more productive. And because the sector is so pertinent, there’s less chance of buying a value trap (though that risk is never zero). On this note, below are compelling and undervalued healthcare stocks to consider. Novartis (NVS) Source: Denis Linine / Shutterstock.com Based in Switzerland, Novartis (NYSE: NVS ) falls under the drug manufacturing space of the healthcare ecosystem. Per its public profile , Novartis engages in the research, development, manufacture and marketing of healthcare products. Primarily, it offers prescription medicines in therapeutic areas, such as cardiovascular, renal and metabolic.
Liquidia stock retook its 50-day line on a U.S. judge''s ruling on a patent dispute with United Therapeutics.
United Therapeutics Corporation (UTHR) share price today is $316.04
Yes, Indians can buy shares of United Therapeutics Corporation (UTHR) on Vested. To buy United Therapeutics Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in UTHR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of United Therapeutics Corporation (UTHR) via the Vested app. You can start investing in United Therapeutics Corporation (UTHR) with a minimum investment of $1.
You can invest in shares of United Therapeutics Corporation (UTHR) via Vested in three simple steps:
The 52-week high price of United Therapeutics Corporation (UTHR) is $311.3. The 52-week low price of United Therapeutics Corporation (UTHR) is $208.62.
The price-to-earnings (P/E) ratio of United Therapeutics Corporation (UTHR) is 14.96
The price-to-book (P/B) ratio of United Therapeutics Corporation (UTHR) is 1.83
The dividend yield of United Therapeutics Corporation (UTHR) is 0.00%
The market capitalization of United Therapeutics Corporation (UTHR) is $14.02B
The stock symbol (or ticker) of United Therapeutics Corporation is UTHR